Semaglutide boosts walking ability in diabetes patients with peripheral artery disease, clinical trial finds
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
The Lancet1d
Therapy for mixed dyslipidaemia through ANGPTL3 inhibition
In epidemiological, genetic, and intervention studies, mixed dyslipidaemia, characterised by elevated concentrations of total ...
Medscape2d
Semaglutide Shows Major Benefits in Peripheral Arterial Disease: STRIDE
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
Gogi Tech3d
10 Must-Have Blood Sugar Monitors for Effortless Home Testing (Find Out Why)
Blood sugar monitoring has never been more convenient, thanks to the latest advancements in technology. For those managing diabetes, having a reliable ...
2025 Research | United States Diabetes Monitoring, Treatment and Drug Delivery Market to Reach $79 Billion by 2031
The "Diabetes Monitoring, Treatment and Drug Delivery Market Size, Share & Trends Analysis | United States | 2025-2031 | MedSuite | Includes: Insulin & GLP-1, Continuous Glucose Monitoring and 7 more" ...